Advair approved for the young
The US Food and Drug Administration (FDA) has approved the use of GSK's Advair 100/50 in children four years to eleven years of age with asthma who are symptomatic on inhaled corticosteroid therapy alone.
The US Food and Drug Administration (FDA) has approved the use of GSK's Advair 100/50 in children four years to eleven years of age with asthma who are symptomatic on inhaled corticosteroid therapy alone.
Advair contains an inhaled corticosteroid (ICS) and a long-acting beta2-agonist (LABA) and is the only long-term preventative product that treats the two main components of asthma - airway inflammation and bronchoconstriction. According to the National Institutes of Health's treatment guidelines, an ICS in conjunction with a LABA is a preferred treatment for patients who still have symptoms while taking low dose ICS.
'Advair is a highly effective treatment for asthma, and it is great news that it is now available for children as young as four,' said Dr Joseph Spahn, associate professor of Pediatrics at National Jewish Medical Center and University of Colorado Health Sciences Center. 'Not only will it help prevent asthma symptoms, but its twice daily dosing is convenient for both parents and children.'